Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P05412 (
c-Jun
)
11,453
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The human
cytochrome P450 2J2
(
CYP2J2
) generates cytoprotective epoxyeicosatrienoic acids from arachidonic acid. Expression of
CYP2J2
is decreased in hypoxia, and the resultant decrease in
CYP2J2
-derived epoxyeicosanoids may contribute to the pathogenesis of cardiac ischaemia. Recent studies have indicated that AP-1 (activator protein-1) regulates
CYP2J2
expression in normoxia and hypoxia. Down-regulation of
CYP2J2
in hypoxic HepG2 cells was closely associated with the up-regulation of c-fos and transient transfection analysis demonstrated that c-Fos abolishes the activation of
CYP2J2
by the AP-1 protein
c-Jun
. Deletion of the region between nt -122 and -50 upstream of the start codon in
CYP2J2
prevented
c-Jun
transactivation. In this study we demonstrate that the sequence at -105/-95 is a major regulatory element that binds
c-Jun
and has a prominent role in
CYP2J2
gene transactivation. Mutagenesis of both the -105/-95 region and the previously identified element at -56/-63 was required for complete loss of transactivation by
c-Jun
; separate mutagenesis of the -105/-95 element or, to a lesser extent, the -56/-63 element resulted in a partial loss of gene activation. In contrast to the behaviour of the -56/-63 element,
c-Jun
homodimers and c-Fos/
c-Jun
heterodimers bound to the -105/-95 element. These findings demonstrate that the
c-Jun
-responsive module between -122 and -50 in the
CYP2J2
proximal promoter contains an atypical AP-1 element at -105/-95 that has a major role in
c-Jun
transactivation and acts in conjunction with the -56/-63 element to regulate expression.
...
PMID:Characterization of a c-Jun-responsive module in the 5'-flank of the human CYP2J2 gene that regulates transactivation. 1600 25